Literature DB >> 33492919

Transforaminal Epidural Steroid Injections: A Systematic Review and Meta-Analysis of Efficacy and Safety.

Standiford Helm Ii1, Preston C Harmon2, Carl Noe3, Aaron K Calodney2, Alaa Abd-Elsayed4, Nebojsa Nick Knezevic5, Gabor B Racz.   

Abstract

BACKGROUND: Transforaminal epidural injections have been used since the late 1990s to treat lumbar radicular pain. They have been the subject of considerable attention, with varying conclusions from systematic reviews as to their efficacy. Transforaminal injections have been associated with rare but major complications. Further, the use of transforaminal injections has increased since the passage of the Affordable Care Act. Finally, with the SARS-CoV-2 pandemic, there has been heightened concern regarding the risk associated with steroid injections.
OBJECTIVES: To evaluate and update the effectiveness of transforaminal injections for 4 indications: radicular pain; from spinal stenosis; from failed back surgery syndrome; and for axial low back pain; and to evaluate the safety of the procedure. STUDY
DESIGN: A systematic review and meta-analysis of the efficacy of transforaminal injections.
METHODS: The available literature on transforaminal injections was reviewed and the quality assessed. The level of evidence was classified on a 5-point scale based on the quality of evidence developed by the US Preventive Services Task Force (USPSTF) and modified by the American Society of Interventional Pain Physicians (ASIPP). Data sources included relevant literature from 1966 to April 2020, and manual searches of the bibliographies of known primary and review articles. Pain relief and functional improvement were the primary outcome measures. A minimum of 6 months pain relief follow-up was required.
RESULTS: For this systematic review, 66 studies were identified. Eighteen randomized controlled trials met the inclusion criteria. No observational studies were included. Eleven randomized controlled trials dealt with various aspects of transforaminal injections for radicular pain owing to disc herniation. Based on these studies, there is Level 1 evidence supporting the use of transforaminal injections for radicular pain owing to disc herniation. A meta-analysis showed that at both 3 and 6 months, there was highly statistically significant improvement in both pain and function with both particulate and nonparticulate steroids. For radicular pain from central stenosis there is one moderate quality study, with Level IV evidence. For radicular pain caused by failed back surgery syndrome there is one moderate quality study, with Level IV evidence. For radicular pain from foraminal stenosis and for axial pain there is Level V evidence, opinion-based/consensus, supporting the use of transforaminal injections. Transforaminal injections are generally safe. However, they have been associated with major neurologic complications related to cord infarct. Causes other than intraluminal injection of particulates appear to be at play. The use of an infraneural approach and of blunt needles appear to offer the greatest patient safety. Because of concern over the role of particulate steroids, multiple other injectates have been evaluated, including nonparticulate steroids, tumor necrosis factor alpha (TNF-a) inhibitors, and local anesthetics without steroids. No injectate has been proven superior. If there is concern about immunosuppression because of risk of COVID-19 infection, either the lowest possible dose of steroid or no steroid should be used. LIMITATIONS: The study was limited by the paucity of literature for some indications.
CONCLUSIONS: There is Level I evidence for the use of transforaminal injections for radicular pain from disc herniations.

Entities:  

Keywords:  axial low back pain zzm321990; epidural steroid injection; post lumbar surgery syndrome; radicular pain; spinal pain; spinal stenosis; transforaminal injection; Disc herniation

Year:  2021        PMID: 33492919

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  7 in total

Review 1.  An update on epidural steroid injections: is there still a role for particulate corticosteroids?

Authors:  Francis T Delaney; Peter J MacMahon
Journal:  Skeletal Radiol       Date:  2022-09-29       Impact factor: 2.128

Review 2.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

3.  Relationship between needle depth for lumbar transforaminal epidural injection and patients' height and weight using magnetic resonance imaging.

Authors:  Hyunji John; Kyomin Sohn; Jae Hun Kim
Journal:  Korean J Pain       Date:  2022-07-01

Review 4.  Chinese Association for the Study of Pain: Expert consensus on diagnosis and treatment for lumbar disc herniation.

Authors:  Zhi-Xiang Cheng; Yong-Jun Zheng; Zhi-Ying Feng; Hong-Wei Fang; Jin-Yuan Zhang; Xiang-Rui Wang
Journal:  World J Clin Cases       Date:  2021-03-26       Impact factor: 1.337

5.  Intradiscal injection for the management of low back pain.

Authors:  Fu Zhang; Songjuan Wang; Baoliang Li; Wei Tian; Zhiyu Zhou; Shaoyu Liu
Journal:  JOR Spine       Date:  2021-12-22

6.  Multidisciplinary Care of a Vertebral Fracture in a Patient with Hematopoietic Stem Cell Transplant: Safety Appropriateness in Interventional Pain Management and Rehabilitation Considerations.

Authors:  Vinicius Tieppo Francio; Brandon Barndt; Usman Latif; Sarah M Eickmeyer
Journal:  Healthcare (Basel)       Date:  2022-03-08

7.  Transforaminal lumbar puncture for spinal anesthesia or novel drug administration: a technique combining C-arm fluoroscopy and ultrasound.

Authors:  Charles Berde; Anna Formanek; Asif Khan; Carlos Rafael Camelo; Anjali Koka; Bobbie L Riley; Horacio Padua
Journal:  Reg Anesth Pain Med       Date:  2022-03-23       Impact factor: 6.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.